Last checked at 29 Aug 2014 05:24
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Reneuron Share News (RENE)
RENE Share
Price
RENE Share
News
RENE Share
Chat
RENE Share
Trades
RENE
Live RNS1
RENE Share
Charts
RENE Level 2
Console
RENE Live
Share Price
RENE Broker
Ratings
RENE Directors
Deals
RENE Financial
Diary
RENE
Fundamentals
RENE Short
Positions
RENE
Media
Reneuron Information
- This share is currently suspended. It was suspended at a price of 3.275
Share Price Information for Reneuron (RENE)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.275
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
0.00 (0.00%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
3.275
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.ReNeuron upbeat on progress in hRPC study
Thu, 04th Apr 2019 14:19
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study. The AIM-traded company had reported in February that all three of the first cohort of subjects in the study had reported a "rapid and significant" improvement in vision, on average equivalent to reading an additional three lines of five letters on the ETDRS eye chart - the standardised eye chart used in clinical trials to measure visual acuity.Last month, it announced that dosing of the second cohort of three phase 2 subjects had begun.That next dose cohort comprised patients who had a greater baseline level of visual acuity than those treated in the study thus far.Further read-outs from the patients treated in the study would be presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada on 26 April.ReNeuron said it would make a further announcement later in April, when those further read-outs from the study were known.The company said its RP clinical programme benefited from 'Orphan Drug Designation' in both Europe and the US, as well as 'Fast Track' designation from the FDA. "We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing phase 1 and 2 study with our hRPC cell therapy candidate for retinitis pigmentosa," said chief executive officer Olav Hellebø."We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."
More News
28 Aug 2014 15:11
28 Aug 2014 05:31
27 Aug 2014 15:25
27 Aug 2014 05:53
26 Aug 2014 15:16
25 Jul 2014 09:40
23 Jul 2014 14:17
Sector movers: Weak results, outlook from Glaxo sink pharma stocks
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read more18 Jun 2014 13:29
ReNeuron well set after 'transformational' year
Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa
Read more18 Jun 2014 11:47
UK MIDDAY BRIEFING: BOE Policy Makers Still Unanimous
LONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.
All nine members of the Monetary Policy
18 Jun 2014 08:27
ReNeuron Confident For Future Despite Loss As It Advances Therapies
LONDON (Alliance News) - ReNeuron Group PLC Wednesday expressed confidence in its future as it continued to develop its stem-cell therapies towards commercialisation, and it posted a widened loss in the year to end-March. The company posted a pretax loss of GBP7.8 million, widened from GBP7
Read more18 Jun 2014 07:21
UK MORNING BRIEFING: Zoopla Prices IPO As Markets Await Central Banks
LONDON (Alliance News) - UK shares have opened higher Wednesday, following a firm close on Wall Street and ahead of central bank announcements in the UK and US.
There was further IPO activity Wednesday, as property website Zoopla Property Group said it will price it
7 May 2014 14:15
ReNeuron Says Stroke Disability Therapy Study Yielding "Encouraging" Results
LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results. The company said that there was no cell-related or immunological adverse events report
Read more23 Apr 2014 12:02
ReNeuron seeks to expand board with new CEO
A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:
Read more23 Apr 2014 11:37
ReNeuron Seeking New Chief Executive, Current To Become Financial Officer
LONDON (Alliance News) - ReNeuron Group PLC said Wednesday that it was appointing a new Chief Executive Officer to replace Michael Hunt, who will be moving into the role of Chief Financial Officer when a successor has been recruited. The company said that, as a result of the progress it has
Read more